{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:01:14Z","timestamp":1792051274419,"version":"4.4.0"},"reference-count":86,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100009736","name":"Freiwillige Akademische Gesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Drug Safety"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There has been notable progress in pharmacovigilance (PV) in low- and middle-income countries (LMIC) in the last decade. However, only a few of these PV systems are fully functional, unlike in high-income countries where stringent legislation, regulations and operational guidelines have enabled the establishment of effective PV systems. The key challenges faced in LMIC include organisational inefficiencies; weak infrastructure; inconsistent and poorly enforced regulations; and inadequate financing and shortage of trained personnel. Furthermore, low adverse event volume and poor data quality hinder the capacity for safety data generation and utilisation. With the increasing availability of essential and innovative medicines in LMIC, establishing robust PV systems is crucial for effective safety surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This research aims to analyse the development of PV systems across high-, middle- and low-income countries and to carve out essential elements for functionality and sustainability of PV systems in LMIC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A convergent parallel mixed-methods design, combining qualitative and quantitative methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Qualitative and quantitative research consisted of semi-structured interviews and an online survey, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twelve key informants from 10 countries were interviewed and 52 respondents from 36 countries completed the online survey. From the qualitative and quantitative data, we identified nine essential elements for sustainable PV development in LMIC: understanding the drivers of PV development; adequately resolving core system challenges; implementing an efficient organisational structure and good governance; establishing procedures for PV activities; ensuring availability of qualified and trained staff; identifying alternate sources of financing; having a strategic development plan; adequately leveraging the health system; and effectively integrating the pharmaceutical sector in the national PV system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Findings from this research indicate that significant efforts are still needed to upgrade PV systems in LMIC to meet global standards despite the progress achieved in recent years. Developing the different areas emerging from this research, within the framework of a holistic, fit-for-purpose PV system strengthening, would enable a comprehensive progression from basic to functional and thus sustainable PV systems in LMIC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20420986251342941","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T04:46:33Z","timestamp":1749530793000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Building functional and sustainable pharmacovigilance systems: an analysis of pharmacovigilance development across high-, middle- and low-income countries"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-4288","authenticated-orcid":false,"given":"Olga","family":"Menang","sequence":"first","affiliation":[{"name":"Department of Medicine, Swiss Tropical and Public Health Institute, Kreuzstrasse 2, Allschwil 4123, Switzerland"},{"name":"University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7594-0166","authenticated-orcid":false,"given":"Peter","family":"van Eeuwijk","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Allschwil, Switzerland"},{"name":"University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0498-0803","authenticated-orcid":false,"given":"Karen","family":"Maigetter","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Allschwil, Switzerland"},{"name":"University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5621-2676","authenticated-orcid":false,"given":"Andrea","family":"de Soyres-Kuemmerle","sequence":"additional","affiliation":[{"name":"Department of Medicine, Swiss Tropical and Public Health Institute, Allschwil, Switzerland"},{"name":"University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7056-8991","authenticated-orcid":false,"given":"Edinam","family":"Agbenu","sequence":"additional","affiliation":[{"name":"World Health Organisation Regional Office for Africa, Ouagadougou, Burkina Faso"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-1984","authenticated-orcid":false,"given":"Christian","family":"Burri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Swiss Tropical and Public Health Institute, Allschwil, Switzerland"},{"name":"University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"World Health Organisation. The importance of pharmacovigilance-safety monitoring of medicinal products https:\/\/iris.who.int\/bitstream\/handle\/10665\/42493\/a75646.pdf?sequence=1 (2002 accessed 20 October 2023)."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfr088"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-131-8_36"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-125"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0281-0"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-019-4651-7"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01319-y"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-022-00443-8"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14851"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2021.12.007"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.07.013"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/20420986221118972"},{"key":"e_1_3_4_14_2","unstructured":"WHO. COVID-19 vaccines: safety surveillance manual https:\/\/iris.who.int\/bitstream\/handle\/10665\/345178\/9789240032781-eng.pdf?sequence=1 (2020 accessed 5 July 2023)."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy11010010"},{"key":"e_1_3_4_16_2","unstructured":"European Commission. Strengthening pharmacovigilance to reduce adverse effects of medicines https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/de\/MEMO_08_782 (2008 accessed 1 October 2023)."},{"key":"e_1_3_4_17_2","unstructured":"European Commission. Directive 2010\/84\/EC of the European Parliament and of the Council of 5 December 2010 amending as regards pharmacovigilance Directive 2001\/83\/EC on the Community code relating to medicinal products for human use https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN:PDF (2010 accessed 1 September 2023)."},{"key":"e_1_3_4_18_2","unstructured":"European Commission. Regulation (EC) No. 1235\/2010 of the European Parliament and of the Council of 15 December 2010 amending as regards pharmacovigilance of medicinal products for human use Regulation (EC) No. 726\/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF (2010 accessed 1 September 2023)."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0572-8"},{"key":"e_1_3_4_20_2","unstructured":"European Medicines Agency. Guidelines on good pharmacovigilance practices (GVP). Introductory cover note last updated with release of Addendum III of Module XVI on pregnancy prevention programmes for public consultation https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-release_en.pdf (2022 accessed 20 November 2023)."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/11536390-000000000-00000"},{"key":"e_1_3_4_22_2","unstructured":"Strengthening Pharmaceutical Systems Program. Safety of medicines in SubSaharan Africa: asssessment of pharmacovigilance systems and their performance https:\/\/africapv2012.wordpress.com\/wp-content\/uploads\/2012\/05\/day-1_2_findings-from-the-ssa-study_nwokike.pdf (2011 accessed 15 July 2022)."},{"key":"e_1_3_4_23_2","unstructured":"Bollyky T Stergachis A. A report of the Safety Surveillance Working Group https:\/\/docs.gatesfoundation.org\/documents\/SSWG%20Final%20Report%2011%2019%2013_designed.pdf (2013 accessed 15 July 2022)."},{"key":"e_1_3_4_24_2","unstructured":"World Health Organisation Global Benchmarking Tool (GBT) for evaluation of national regulatory systems of medical products: revision VI https:\/\/www.who.int\/publications\/i\/item\/9789240020245 (2021 accessed 17 July 2024)."},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-071079"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-018-0431-0"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00898-z"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01102-x"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-019-0173-2"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4991"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","unstructured":"Wang H Darko DM Figueras Sune A et al. Ghana\u2019s pharmacovigilance experience: from vertical program activity to nationwide system. Pharmacovigilance and Essential Public Health Services Series. Washington DC: World Bank. http:\/\/hdl.handle.net\/10986\/40382 (2023 accessed 6 July 2024).","DOI":"10.1596\/40382"},{"key":"e_1_3_4_32_2","unstructured":"World Health Organisation. List of National Regulatory Authorities (NRAs) operating at maturity level 3 (ML3) and maturity level 4 (ML4) as benchmarked against WHO Global Benchmarking Tool (GBT) https:\/\/www.who.int\/publications\/m\/item\/list-of-nras-operating-at-ml3-and-ml4 (2024 accessed 11 July 2025)."},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00457"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-022-00415-y"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15193"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4023"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2015.1053391"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098611425695"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.651720"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.10.044"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-023-00669-3"},{"key":"e_1_3_4_42_2","unstructured":"World Health Organisation. Global Vaccine Safety Blueprint (GVSB 1.0) https:\/\/www.who.int\/publications\/i\/item\/WHOIVB12.07 (2012 accessed 1 January 2022)."},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01100-z"},{"key":"e_1_3_4_44_2","unstructured":"WHO. World Health Organisation regional offices https:\/\/www.who.int\/about\/who-we-are\/regional-offices (2024 accessed 21 August 2024)."},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523"},{"key":"e_1_3_4_46_2","unstructured":"The World Bank. World Bank country and lending groups https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups (2023 accessed 1 September 2023)."},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-117"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1177\/10775587211030393"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-003181"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S466039"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01302-7"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932010-00002"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10061015"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2224558"},{"key":"e_1_3_4_56_2","unstructured":"European Medicines Agency. Pharmacovigilance in 2018 https:\/\/www.ema.europa.eu\/en\/documents\/other\/presentation-pharmacovigilance-2018-p-arlett_en.pdf (2018 accessed 20 November 2023)."},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0123-x"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2022.866898"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15669"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19052518"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-017-0570-z"},{"key":"e_1_3_4_62_2","unstructured":"Pharmacovigilance Africa. Lessons and best practices from the PAVIA project: a blueprint for strengthening pharmacovigilance systems in resource-limited countries https:\/\/media.tghn.org\/medialibrary\/2023\/05\/Pavia_Blueprint_FINAL.pdf (2023 accessed 20 September 2023)."},{"key":"e_1_3_4_63_2","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module I \u2013 Pharmacovigilance systems and their quality systems https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-module-i-pharmacovigilance-systems-their-quality-systems_en.pdf (2012 accessed 5 October 2023)."},{"key":"e_1_3_4_64_2","unstructured":"Strengthening Pharmaceutical Systems Program. Supporting pharmacovigilance in developing countries: the systems perspective https:\/\/www.gims-foundation.org\/wp-content\/uploads\/2016\/06\/Supporting-Pharmacovigilance-in-developing-countries-2009.pdf (2009 accessed 29 January 2024)."},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00807-4"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2016.09.008"},{"key":"e_1_3_4_67_2","unstructured":"World Bank Group. Ghana\u2019s pharmacovigilance experience: from vertical program activity to nationwide system https:\/\/openknowledge.worldbank.org\/server\/api\/core\/bitstreams\/cbdfca6a-fab1-4524-a4e3-96539206a0db\/content (2023 accessed 20 October 2024)."},{"key":"e_1_3_4_68_2","unstructured":"European Medicines Agency. Explanatory note on pharmacovigilance fees payable to the European Medicines Agency https:\/\/www.ema.europa.eu\/en\/documents\/other\/explanatory-note-pharmacovigilance-fees-payable-ema-4-october-2023_en.pdf (2023 accessed 5 October 2023)."},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1177\/20420986231188836"},{"key":"e_1_3_4_70_2","unstructured":"Netherlands Pharmacovigilance Centre Lareb https:\/\/www.lareb.nl\/en (2024 accessed 2 September 2024)."},{"key":"e_1_3_4_71_2","unstructured":"Netherlands Medicines Evaluation Board https:\/\/english.cbg-meb.nl\/topics\/about-meb-integrity-openness-and-finances (2024 accessed 2 September 2024)."},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-017-0210-x"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.120941"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236332"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0708-5"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00925-4"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1173291"},{"key":"e_1_3_4_78_2","unstructured":"African Union Development Agency. African Union smart safety surveillance (AU-3S) https:\/\/www.nepad.org\/microsite\/african-union-smart-safety-surveillance-au-3s (2022 accessed 5 May 2024)."},{"key":"e_1_3_4_79_2","unstructured":"Working Group 3 Vigilance. South-East Asia Regulatory Network Working Groups https:\/\/searn-network.org\/working-groups\/wg3-vigilance (2024 accessed 3 August 2024)."},{"key":"e_1_3_4_80_2","unstructured":"Dowling P. Healthcare supply chains in developing countries: situational analysis. USAID Deliver Project Task Order 4 https:\/\/peoplethatdeliver.org\/sites\/default\/files\/2022-01\/Healthcare%20Supply%20Chains%20-%20Situation%20Analysis%20EN.pdf (2011 accessed 20 October 2023)."},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.029"},{"key":"e_1_3_4_82_2","unstructured":"African Union Development Agency. African Medicines Agency (AMA) https:\/\/www.nepad.org\/microsite\/african-medicines-agency-ama (2022 accessed 5 May 2024)."},{"key":"e_1_3_4_83_2","volume-title":"Pharmacovigilance processes in low- and middle-income countries: moving from data collection to data analysis and interpretation","author":"Menang O","year":"2024","unstructured":"Menang O, van Eeuwijk P, Maigetter K, et al. Pharmacovigilance processes in low- and middle-income countries: moving from data collection to data analysis and interpretation. Basel: Swiss Tropical and Public Health Institute, 2024."},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4906"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2022.104895"},{"key":"e_1_3_4_86_2","unstructured":"Uppsala Monitoring Centre. VigiLyse https:\/\/who-umc.org\/pv-products\/vigilyze\/ (2024 accessed 22 August 2024)."},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.665584"}],"container-title":["Therapeutic Advances in Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986251342941","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420986251342941","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986251342941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:40:57Z","timestamp":1777592457000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420986251342941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":86,"alternative-id":["10.1177\/20420986251342941"],"URL":"https:\/\/doi.org\/10.1177\/20420986251342941","relation":{},"ISSN":["2042-0986","2042-0994"],"issn-type":[{"value":"2042-0986","type":"print"},{"value":"2042-0994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"article-number":"20420986251342941"}}